Kilitch Drugs (India) approves unaudited Q2 and half-year results to 30 Sept 2026
Kilitch Drugs (India) · Pharmaceuticals & Biotechnology
Key highlights
- Board approved standalone and consolidated unaudited results for the quarter and half year ended 30 Sept 2026 on 6 Nov 2026.
- Consolidated profit after tax for the quarter was Rs. 141.24 lakh, against Rs. 804.00 lakh in the year-earlier quarter.
- Auditor's limited review reported nothing to suggest material misstatement; consolidated total assets were Rs. 46,430.34 lakh at 30 Sept 2026.
Why it's rated major development: the year-on-year change is 82% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Unaudited Financial Results
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other financial results filings this fortnight
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
- Mangalam Seeds approves Q2 results, divests subsidiary and associate stakes
- HCP Plastene Bulkpack reports Sep 2026 quarter results; Aman Parekh named CFO
- Indo Borax & Chemicals reports unaudited results for quarter and half year to 30 Sep 2026
- Voltas Limited announces Unaudited Financial Results for Q2 and H1 FY2026-27
- Innovators Façade Systems approves unaudited results for half year ended Sept 30, 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.